Management Team And Advisors
Paolo Daniele Siviero, MS Pharm: President
Giorgio Mari, MS Chemistry: Chief Executive Officer
Massimo Dominici, MD: Scientific Founder and Consultant
Pierfranco Conte, MD, PhD: Medical Oncology Advisor and Co-Founder
Paolo Paolucci, MD: Advisor 
Alberto Luppi: Accountant

Rigenerand Therapeutics (Thera)
Laura Fiammenghi, PhD: Qualified Person
Carlotta Spano, PhD: Head of cGMP manufacturing
Giulia Grisendi, PhD: Responsible R&D
Angela D’esposito, PhD: Scientist R&D
Federico Ganzerli, MS Engineering: Quality Assistant Specialist

Rigenerand Biodisposable (BioDi)
Olivia Candini, PhD: Responsible Cell and Tissue Engenering R&D
Matteo Brogli, BS: Responsible Disposable R&D and Manufacturing
Elisabetta Foppiani, PhD: Scientist R&D

Management Team And Advisors

Paolo Daniele Siviero, MS

Giorgio Mari, MS


MS in chemistry active in the biomedical field since 1980. He has contributed to the development of Miramed Srl (Baxter) (1980-1990), to the creation of Biofil Srl (1990-1993) and Fresenius HemoCare Italia Srl (1994-2012).
Head of R&D Projects at Tecno Polo Mirandola (TPM), and CEO in Rigenerand Srl.

Massimo Dominici, MD


MD degree at the University of Pavia and post-graduate internship at the Vienna University (Austria). Residency in Hematology at the University of Ferrara. Post-Doctoral Associate at St. Jude Children’s Hospital in Memphis (USA). Currently hospital physician, associate professor of Medical Oncology, head of the laboratory of cellular therapies at the Modena and Reggio Emilia University, director of the residency school in Medical Oncology and faculty of the PhD school of Molecular and Regenerative Medicine in the same University. More than 120 papers published with over 14000 citations. Co-founder and co-coordinator of the Mirandola Science & Tecnology Park. He has been co-founder of the Forum of Italian Researcher on MSC (FIRST), board member of JACIE, WBMT and scientific advisor for the Italian Minister of Health. He has been member of ISCT, ASH, ESCGT, IFATS, IPLASS. Past President of ISCT, now Chair of the Advisory Board and Chair of the Presidential Task Force on Unproven Cell Therapies. He is the scientific founder, member of the board and consultant of Rigenerand.

Pierfranco Conte, MD, PhD

Paolo Paolucci, MD

Alberto Luppi


Alberto has over twenty years experience in the accounting and purchase fields working for several companies. Since 1994 purchasing manager at Office Systems Srl, from 2001 accounting manager at P.M. Srl then Polidatasystem Srl, in 2004 accounting manager at Domina Srl. Since 2016 Alberto is the company accountant in Rigenerand.

Rigenerand Therapeutics (Thera)

Laura Fiammenghi, PhD


MS in Biology and Postgraduate Degree in Toxicology at the University of Bologna. PhD in Immunology and Cellular biology at the University of Torino. Laura has constantly developed patient-oriented projects in the field of immunotherapy. She has over ten years of experience in cGMP-manufacturing of immuno effector cells such as dendritic cell vaccines at the IRST in Meldola. She is the Qualified Person in Rigenerand Therapeutics.

See Laura’s Publications

Maria Carlotta Spano, PhD


MS in Medical Biotechnology and PhD in Molecular and Regenerative Medicine at the University of Modena and Reggio Emilia. Carlotta has developed projects aimed at the establishment of cancer gene therapy strategies by engineered T lymphocytes and adult stem cells. She is the head of manufacturing in Rigenerand Therapeutics.

See Carlotta’s Publications

Giulia Grisendi, PhD


MS in Medical Biotechnology and PhD in Molecular and Regenerative Medicine at the University of Modena and Reggio Emilia. Additional Master Degree in Clinical and Experimental Flow Cytometry at the University of Urbino. Giulia has been involved in pre-clinical projects focusing on adult stem cell biology and their genetic engineering for cancer therapies. She is heading the R&D division of Rigenerand Therapeutics.

See Giulia’s Publications

Angela D’esposito, PhD


MS in Biomedical Engineering at Sapienza, University of Rome. PhD in Medical Physics at the Centre for Advanced Biomedical Imaging, University College of London (London, UK). Angela has developed new imaging techniques to investigate the effect of cancer therapies on tumour models in vivo. She is a scientist in the R&D Division of Rigenerand Therapeutics.

See Angela’s Publications

Federico Ganzerli, MS


With a MS degree in Electrical Engineeering, Federico has been covering the role of plant maintenance, environmental, health & safety Manager in several multinational healthcare companies (Biofil and Fresenius).
He is currently the Quality Assistant Specialist in Rigenerand.

Rigenerand Biodisposable (BioDi)

Matteo Brogli, BS


With a Biotechnology BS degree from the University of Ferrara, Matteo has been constantly working in the development of solutions for human diseases by biomedical devices. In 1999 he developed a bio-artificial liver support systems at University-Hospital of Ferrara. From 2004 he was in the R&D disposable division of Rand-Biotech contributing to the development and patenting of several bioreactors and culture systems for human and animal cells. Since 2016 he is in charge of the disposable R&D and manufacturing of Rigenerand Biodisposable division.

See Matteo Publications

Olivia Candini, PhD


MS in Medical Biotechnology and PhD in Experimental Medicine at the University of Modena and Reggio Emilia. Olivia has been deeply engaged in projects aimed to better understand the impact of human aging and other determinants on mesenchymal progenitor properties for the development of innovative approaches to enhance MSC performance in tissue regeneration. She is now responsible of cell and tissue engineering R&D in Rigenerand Biodisposable division also collaborating with the Therapeutic division.

See Olivia’s publications

Elisabetta Manuela Foppiani, PhD


MS in Medical and Pharmaceutical Biotechnology at the University of Pavia (Italy). PhD in Molecular and Regenerative Medicine at the University of Modena and Reggio Emilia. Elisabetta has been working on the development of projects aimed at the ex-vivo optimization of adult stem cell performance. She is now a R&D scientist in the Rigenerand Biodisposable division.